PCM
VRTX icon

Palouse Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Palouse Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,049
Closed -$1.24M – 152
2023
Q4 		$1.24M Buy
3,049
+12
+0.4% +$4.43K 0.88% 50
2023
Q3 		$1.06M Buy
3,037
+1
+0% +$350 0.78% 55
2023
Q2 		$1.07M Sell
3,036
-218
-7% -$73.5K 0.75% 56
2023
Q1 		$1.03M Sell
3,254
-931
-22% -$279K 0.69% 59
2022
Q4 		$39.9M Sell
4,185
-281
-6% -$85.6K 2.76% 11
2022
Q3 		$1.29M Sell
4,466
-127
-3% -$36.5K 0.73% 54
2022
Q2 		$1.29M Sell
4,593
-1,803
-28% -$483K 0.64% 59
2022
Q1 		$1.67M Sell
6,396
-222
-3% -$52.7K 0.73% 56
2021
Q4 		$1.45M Sell
6,618
-1,090
-14% -$212K 0.62% 59
2021
Q3 		$1.4M Sell
7,708
-227
-3% -$44.3K 0.62% 59
2021
Q2 		$1.6M Buy
7,935
+140
+2% +$29.3K 0.7% 58
2021
Q1 		$1.68M Buy
7,795
+2,434
+45% +$535K 0.74% 54
2020
Q4 		$1.27M Buy
+5,361
New +$1.23M 0.67% 58

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Palouse Capital Management's VRTX Position: Q1 2024 in Review

Palouse Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 3,049 shares — an estimated $1.24M sold.

Palouse Capital Management first reported a position in VRTX in Q4 2020 and held it in 13 quarters. The position peaked at $39.9M in Q4 2022. 1,494 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Palouse Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Palouse Capital Management sold 3,049 Vertex Pharmaceuticals shares in Q1 2024, an estimated $1.24M.
  • Palouse Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 13 quarters.
  • Palouse Capital Management's Vertex Pharmaceuticals position peaked at $39.9M in Q4 2022.
  • 1,494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Palouse Capital Management's 13F filing for Q1 2024, filed 15 May 2024.